Growth hormone, lipoprotein(a) and cardiovascular disease

European Heart Journal

Volumn 19, Issue 2, 1998, Pages 204-206

  Laron, Z ^a   Wang, X L ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HEXARELIN; LIPOPROTEIN A;

CARDIOVASCULAR DISEASE; EDITORIAL; GROWTH DISORDER; HORMONAL THERAPY; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

CARDIOVASCULAR DISEASES; HUMAN GROWTH HORMONE; HUMANS; LIPOPROTEIN(A);

EID: 0031905194     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0585     Document Type: Editorial

References (35)

1. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 401-3.
2. Laron Z, Butenandt O, Raiti S. Clinical use of growth hormone - present and future aspects. Pediat Adolesc Endocrinol 1987; 16: 269.
3. Laron Z, Butenandt O. Optimum use of growth hormone in children (Review). Drugs 1991; 42: 1-8.
4. Merola B, Cittadini A, Colac A, Longobardi S, Fazio S, Sabatini D, Sacca L, Lombardi G. Cardiac structural and functional association in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993; 77: 1658-61.
5. Christiansen JS, Jorgensen JOL, Thuesen L. Cardiovascular aspects of growth hormone replacement therapy in adults. Endocrinol Metab 1996; 3 (Suppl A): 19-22.
6. Thorner MO, Vancxe ML, Horvath C, Kovacs K. The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology, 8th edn. Philadelphia, London: W. B. Saunders Co, 1992: 272.
7. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien R, Ross Jr J. Insulin-like growth factor enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 45: 619-27.
8. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-7.
9. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 808-14.
10. Laron Z, Butenandt O. Growth hormone replacement therapy in adults - pros and cons. Tel Aviv/London: Freund Publishing House Ltd., 1993: 188.
11. Johannsson G, Bjarnason R, Bramnert M et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH binding protein, body mass index, age and gender. J Clin Endocrinol Metab 1996; 81: 1575-81.
12. Turner H, Wass JAH. Growth hormone in the treatment of dilated cardiomyopathy (letter). N Engl J Med 1996; 335: 672.
13. Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy (letter). N Engl J Med 1996; 335: 672.
14. Lawn RM. Lipoprotein(a) in heart disease. Sci Amer 1992; 266: 54-60.
15. Durrington PN. Lipoprotein(a) Balliere's Clin Endocrinol Metab. 1995; 9: 773-95.
16. Wade DP. Lipoprotein(a). Current Opinion Lipidol 1993; 4: 244-9.
17. Harpel PC, Gordon BR, Parker TS. Plasmin catalyses binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847-51.
18. Wilcken DEL, Wang XL, Greenwood J, Lynch J. Lipoprotein(a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents. J Pediatr 1993; 123: 519-26.
19. Kuusi T, Yki-Jarvinen H, Kauppinen-Makelin R et al. Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. Eur J Clin Invest 1995; 25: 194-200.
20. Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. Arch Int Med 1996; 156: 866-72.
21. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA. Growth hormone treatment of growth hormone - deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993; 13: 296-301.
22. Oscarsson J, Ottosson M, Wiklund O, et al. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased density lipoprotein cholesterol concentrations in middle-aged men. Clin Endocrinol 1994; 41: 109-16.
23. Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B. Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I. Arterioscler Throm Vase Biol 1995; 15: 847-9.
24. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Growth hormone increases and insulin-like growth factor decreases circulating lipoprotein(a). Eur J Endocrinol 1997; 136: 377-81.
25. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure. J Pediat Endocrinol Metab 1996; 9: 533-7.
26. Garry P, Collins P, Devlin JG. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 1996; 134: 61-6.
27. Hershkovitz E, Leiberman E, Limony Y, Shany Sh, Phillip M. Short-term growth hormone increases serum lipoprotein(a) levels in normal short children without growth hormone deficiency. Horm Res 1996; 46: 38-40.
28. Querfeld U, Haffner D, Wuhl E, et al. Treatment with growth hormone increases lipoprotein(a) serum levels in children with chronic renal insufficiency. Eur J Pediat 1996; 155: 413-8.
29. Lam SL, Pang RWC, Janus ED, Kung AWC. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis 1993; 104: 183-8.
30. Oscarsson J, Lundstam UK, Gustafsson B, Wilton P, Eden S, Wiklund O. Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol 1995; 42: 673-6.
31. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Insulin-like growth factor-I decreases serum lipoprotein(a) during long-term treatment of patients with Laron Syndrome. Metabolism 1996; 45: 1263-66.
32. Dunger DB, Acerini CL, Cheetham TD, Crowne EC. How does rhIGF-I replacement improve insulin sensitivity in insulin dependent diabetes mellitus? J Pediat Endocrinol Metab 1997; 10 (Suppl 1): 117-22.
33. Moses AC. Recombinant human insulin-like growth factor as a therapeutic agent for severe insulin resistance and type II diabetes mellitus. J Pediat Endocrinol Metab 1997; 10 (Suppl 1): 123-30.
34. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
35. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron Syndrome: preliminary results. Clin Endocrinol 1994; 41: 631-8.